PEDIATRICS Vol. 75 No. 2 February 1985, pp. 387-441
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bryla, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bryla, D. A.

Development, Design, and Sample Composition

Dolores A. Bryla MPH1

1 From the Biometry Branch, Epidemiology and Biometry Research Program, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland

Following its introduction in 1947 for treatment of erythroblastosis fetalis and in 1949 for hyperbilirubinemia, exchange transfusion became accepted as the most effective means of preventing increasing serum bilirubin concentrations in the newborn infant from reaching a hazardous level.2 At that time, there was general agreement that the risk of bilirubin encephalopathy increased when serum bilirubin concentrations exceeded 20 mg/dL of serum and that this risk became greater with increasing concentrations. The safety of exchange transfusion was assessed by Boggs and Westphal14 in 1960 and found acceptable for that time.

In 1958, Cremer et al22 reported a distinct lowering of serum bilirubin levels in infants exposed to direct sunlight. This observation was followed by development of light sources for exposure of infants to treat or prevent hyperbilirubinemia (phototherapy).

Although phototherapy had been used and reported in Europe and South America, it was not until 1968 that the first study64 appeared in the pediatric literature of the United States. Other studies36,41,83 followed and suggested a potential role for phototherapy in the management of hyperbilirubinemia of the newborn infant. However, these studies suffered from lack of a sufficient number of patients to accommodate appropriate statistical adjustment procedures for the many known confounding variables. Also, these studies had inadequate numbers of control infants and phototherapy-treated infants who were followed long enough to perform evaluations of the impact of the mode of therapy on such parameters as hearing, sight, speech, IQ, and behavioral performance.31,74

DEVELOPMENT OF THE STUDY

In May 1972, the National Research Council of the National Academy of Sciences established a Committee on Phototherapy in the Newborn.




This article has been cited by other articles:


Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
C V Hulzebos, D E van Imhoff, A F Bos, C E Ahlfors, H J Verkade, and P H Dijk
Usefulness of the bilirubin/albumin ratio for predicting bilirubin-induced neurotoxicity in premature infants
Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2008; 93(5): F384 - F388.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. Ip, M. Chung, J. Kulig, R. O'Brien, R. Sege, S. Glicken, M. J. Maisels, J. Lau, and Subcommittee on Hyperbilirubinemia
An Evidence-Based Review of Important Issues Concerning Neonatal Hyperbilirubinemia
Pediatrics, July 1, 2004; 114(1): e130 - e153.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
K. L. Yeo, M. Perlman, Y. Hao, and P. Mullaney
Outcomes of Extremely Premature Infants Related to Their Peak Serum Bilirubin Concentrations and Exposure to Phototherapy
Pediatrics, December 1, 1998; 102(6): 1426 - 1431.
[Abstract] [Full Text] [PDF]